Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis

Carmona, 2001, The burden of musculoskeletal diseases in the general population of Spain: results from a national survey, Ann Rheum Dis, 60, 1040, 10.1136/ard.60.11.1040 Lard, 2001, Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies, Am J Med, 111, 446, 10.1016/S0002-9343(01)00872-5 Nell, 2004, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, Rheumatology (Oxford), 43, 906, 10.1093/rheumatology/keh199 Grigor, 2004, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet, 364, 263, 10.1016/S0140-6736(04)16676-2 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405 Smolen, 2007, New therapies for treatment of rheumatoid arthritis, Lancet, 370, 1861, 10.1016/S0140-6736(07)60784-3 Fitch, 2001 Rodríguez-Valverde, 2006, III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide, Rev Esp Reumatol, 2, 52 Oxford Centre for Evidence-based Medicine-Levels of Evidence (March 2009). 2009 [accessed 9/22/2009]. Available at: http://www.cebm.net/index.aspx?o=1025 Guía de práctica clínica para el manejo de la artritis reumatoide 2007 (versión HTML completa) [accessed 9/22/2009]. Available at: http://www.ser.es/practicaClinica/GUIPCAR_2007/Menu0_Principal.php GUIPCAR. Principales fármacos modificadores de la enfermedad (FAME) 2007 [accessed 9/22/2009]. Available at: http://www.ser.es/practicaClinica/GUIPCAR _2007/Tablas/Tabla21.php Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Bathon, 2000, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis, N Engl J Med, 343, 1586, 10.1056/NEJM200011303432201 St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 Breedveld, 2004, Infliximab in active early rheumatoid arthritis, Ann Rheum Dis, 63, 149, 10.1136/ard.2003.013961 Sanmartí, 2004, Etanercept en pacientes con artritis reumatoide y escasa respuesta terapéutica a infliximab, Med Clin (Barc), 122, 321, 10.1157/13059029 Van der Heijde, 2006, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis Rheum, 54, 1063, 10.1002/art.21655 Kalden, 2005, Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis, J Rheumatol, 32, 1620 Combe, 2006, Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison, Ann Rheum Dis, 65, 1357, 10.1136/ard.2005.049650 Combe, 2009, Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study, Ann Rheum Dis, 68, 1146, 10.1136/ard.2007.087106 Cohen, 2002, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-fourweek, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 614, 10.1002/art.10141 Fitzgerald, 2005, Rapid responses to anakinra in patients with refractory adult-onset Still's disease, Arthritis Rheum, 52, 1794, 10.1002/art.21061 Dinarello, 2005, Blocking IL-1 in systemic inflammation, J Exp Med, 201, 1355, 10.1084/jem.20050640 Emery, 2006, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis Rheum, 54, 1390, 10.1002/art.21778 Cohen, 2006, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis Rheum, 54, 2793, 10.1002/art.22025 Keystone, 2009, Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies, Ann Rheum Dis, 68, 216, 10.1136/ard.2007.085787 Takk, 2009, Ann Rheum Dis, 68, 75 Kremer, 2006, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial, Ann Intern Med, 144, 865, 10.7326/0003-4819-144-12-200606200-00003 Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, N Engl J Med, 353, 1114, 10.1056/NEJMoa050524 Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 Genovese, 2008, Arthritis Rheum, 58, 2968, 10.1002/art.23940 Jones, 2009, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study, Ann Rheum Dis Emery, 2008, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial, Ann Rheum Dis, 67, 1516, 10.1136/ard.2008.092932 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis, 66, 1162, 10.1136/ard.2006.068064 Nishimoto, 2009, Mod Rheumatol, 19, 12, 10.1007/s10165-008-0125-1 Emery, 2008, Tociluzumab (TCZ) rapidly and significantly improves outcomes in patients with rheumatoid arthritis (RA) who have inadequate response (IR) to TNF antagonists, Arthritis Rheum, 58, S617 Esteve-Vives, 1993, Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency, J Rheumatol, 20, 2116 Van der Heijde, 1993, Development of a disease activity score based on judgment in clinical practice by rheumatologists, J Rheumatol, 20, 579 Van der Heijde, 1992, Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis, Ann Rheum Dis, 51, 177, 10.1136/ard.51.2.177 Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107 Smolen, 2003, A simplified disease activity index for rheumatoid arthritis for use in clinical practice, Rheumatology (Oxford), 42, 244, 10.1093/rheumatology/keg072 Aletaha, 2005, The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis, Clin Exp Rheumatol, 23, S100 Prevoo, 1996, Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score, Br J Rheumatol, 35, 1101, 10.1093/rheumatology/35.11.1101 Balsa, 2004, Value of disease activity score 28 (das28) and das28-3 compared to american college of rheumatology-defined remission in rheumatoid arthritis, J Rheumatol, 31, 40 Aletaha, 2005, Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states, Arthritis Rheum, 52, 2625, 10.1002/art.21235 Castrejon, 2008, Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?, Clin Exp Rheumatol, 26, 769 Radovits, 2008, Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis, Ann Rheum Dis, 67, 1127, 10.1136/ard.2007.079913 Ahlmén, 2009, Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage, Ann Rheum Dis, 69, 230, 10.1136/ard.2008.102244 Leeb, 2007, Disease activity score-28 values differ considerably depending on patient's pain perception and sex, J Rheumatol, 34, 2382 Unruh, 1996, Gender variations in clinical pain experience, Pain, 65, 123, 10.1016/0304-3959(95)00214-6 Quinn, 2001, The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?, Rheumatology (Oxford), 40, 1211, 10.1093/rheumatology/40.11.1211 Boers, 2003, Understanding the window of opportunity concept in early rheumatoid arthritis, Arthritis Rheum, 48, 1771, 10.1002/art.11156 Gonzalez-Alvaro, 2008, Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort, Arthritis Res Ther, 10, R138, 10.1186/ar2561 Breedveld, 2006, Arthritis Rheum, 54, 26, 10.1002/art.21519 Smolen, 2006, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial, Arthritis Rheum, 54, 702, 10.1002/art.21678 Emery, 2008, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial, Lancet, 372, 375, 10.1016/S0140-6736(08)61000-4 Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033 Genovese, 2008, Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy, Ann Rheum Dis, 67, 547, 10.1136/ard.2007.074773 Weinblatt, 2006, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study, Arthritis Rheum, 54, 2807, 10.1002/art.22070 Weinblatt, 2007, Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial, Ann Rheum Dis, 66, 228, 10.1136/ard.2006.055111 Smolen, 2009, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, Lancet, 374, 210, 10.1016/S0140-6736(09)60506-7 Vollenhoven, 2001, Dose escalation of infliximab in clinical practice: Data from the Stockholm TNF registry, Arthritis Rheum, 44, S82 Pavelka, 2009, Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy, Ann Rheum Dis, 68, 1285, 10.1136/ard.2008.090860 Brocq, 2002, [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha], Presse Med, 31, 1836 Hansen, 2004, The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis, J Rheumatol, 31, 1098 Finckh, 2007, B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents, Arthritis Rheum, 56, 1417, 10.1002/art.22520 Doran, 2002, Frequency of infection in patients with rheumatoid arthritis compared with controls: a populationbased study, Arthritis Rheum, 46, 2287, 10.1002/art.10524 Baecklund, 2006, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis Rheum, 54, 692, 10.1002/art.21675 Solomon, 2003, Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis, Circulation, 107, 1303, 10.1161/01.CIR.0000054612.26458.B2 Carmona, 2005, Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación a 14 de enero de 2005, Reumatol Clin, 1, 95, 10.1016/S1699-258X(05)72722-4 Furst, 2003, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, 30, 2563 Genovese, 2002, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes, Arthritis Rheum, 46, 1443, 10.1002/art.10308 Strangfeld, 2009, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA, 301, 737, 10.1001/jama.2009.146 Khanna, 2004, Safety of tumour necrosis factor-alpha antagonists, Drug Saf, 27, 307, 10.2165/00002018-200427050-00003 Salliot, 2009, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Ann Rheum Dis, 68, 25, 10.1136/ard.2007.083188 Gomez-Reino, 2007, Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection, Arthritis Rheum, 57, 756, 10.1002/art.22768 Gomez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report, Arthritis Rheum, 48, 2122, 10.1002/art.11137 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Mohan, 2004, Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor, Clin Infect Dis, 39, 295, 10.1086/421494 Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum, 52, 1766, 10.1002/art.21043 Calabrese, 2006, virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies, Ann Rheum Dis, 65, 983, 10.1136/ard.2005.043257 Parke, 2004, Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection, Arthritis Rheum, 51, 800, 10.1002/art.20702 Zein, 2005, Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study, J Hepatol, 42, 315, 10.1016/j.jhep.2004.11.025 Cansu, 2008, Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis, J Rheumatol, 35, 421 Ferri, 2008, Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection, J Rheumatol, 35, 1944 Cepeda, 2008, The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease, Ann Rheum Dis, 67, 710, 10.1136/ard.2007.081513 Kaine, 2007, Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab, J Rheumatol, 34, 272 Elkayam, 2004, The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis, Semin Arthritis Rheum, 33, 283, 10.1053/j.semarthrit.2003.10.003 Elkayam, 2009, The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis, Semin Arthritis Rheum Gelinck, 2007, Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab, Ann Rheum Dis, 66, 1402, 10.1136/ard.2007.071878 Oren, 2008, Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response, Ann Rheum Dis, 67, 937, 10.1136/ard.2007.077461 Bibbo, 2004, Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy, Foot Ankle Int, 25, 331, 10.1177/107110070402500510 Corrao, 2007, Safety of etanercept therapy in rheumatoid patients undergoing surgery: Preliminary report, Clin Rheumatol, 26, 1513, 10.1007/s10067-007-0534-0 Den Broeder, 2007, Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study, J Rheumatol, 34, 689 Wendling, 2005, Surgery in patients receiving anti-tumour necrosis factor (alpha) treatment in rheumatoid arthritis: An observational study on 50 surgical procedures, Ann Rheum Dis, 64, 1378, 10.1136/ard.2005.037762 Giles, 2006, Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis, Arthritis Care Res, 55, 333, 10.1002/art.21841 Scott, 2006, Tumor necrosis factor inhibitors for rheumatoid arthritis, N Engl J Med, 355, 704, 10.1056/NEJMct055183 Sibilia, 2007, Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis, Clin Exp Rheumatol, 25, S46 Abasolo, 2008, Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population, Semin Arthritis Rheum, 37, 388, 10.1016/j.semarthrit.2007.08.006 Geborek, 2005, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis, 64, 699, 10.1136/ard.2004.030528 Okada, 2006, Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis, JAMA, 296, 2201, 10.1001/jama.296.18.2201-b Setoguchi, 2008, Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis, Am Heart J, 156, 336, 10.1016/j.ahj.2008.02.025 Curtis, 2007, Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists, Rheumatology (Oxford), 46, 1688, 10.1093/rheumatology/kem212 Martin, 2006, Severe fatal cpmplications associated with infliximab therapy in rheumatoid arthritis, J Rheumatol, 33, 380 Ostor, 2006, Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis, J Rheumatol, 33, 622 Simsek, 2007, Optic neuritis occurring with antitumour necrosis factor alpha therapy, Ann Rheum Dis, 66, 1255, 10.1136/ard.2006.066787 Bensouda-Grimaldi, 2007, Adalimumabassociated multiple sclerosis, J Rheumatol, 34, 239 Keystone, 2005, Safety of biologic therapies–an update, J Rheumatol Suppl, 74, 8, 10.1093/rheumatology/keh617 Ostensen, 2008, Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs, Rheumatology (Oxford), 47, iii28, 10.1093/rheumatology/ken168